StreetAlpha.app
Home › Stocks › BBIO

BridgeBio Pharma, Inc. (BBIO)

Healthcare
$76.03
▼ −2.75%
LAST CLOSE · NOV 20

BridgeBio Pharma develops medicines for patients with genetic diseases, with its main product being Attruby for a heart condition. It last closed at $76.03 on Nov 20, down 2.75% on the day. The next earnings report for BBIO is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, BBIO reported EPS of -$0.42 on revenue of $353.2M, with revenue up 192.6% from a year ago. Over its last 8 reports the stock moved an average of 4.0% the session after earnings. Over the last 12 months BBIO insiders bought $0 of stock on the open market and sold $90.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is BBIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BBIO.

Key Stats

Last 12 months
Results
Revenue
$945.5M
+167.3% vs a year ago
Net income
−$573.8M
−60.7% margin
EPS (diluted)
−$3.03
Free cash flow
−$369.8M
−39.1% margin
Valuation
Market cap
$14.8B
194.8M shares
P/E
–
No P/E while losing money
Price to sales
15.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.5B
At Sep 30
Debt
$2.6B
At Sep 30
Shareholder equity
−$1.7B
Buybacks
$252.5M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $69.7M$69.7MFY2021FY2022: $77.6M$77.6MFY2022FY2023: $9.3M$9.3MFY2023FY2024: $221.9M$221.9MFY2024FY2025: $502.1M$502.1MFY2025

From BBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
-$0.42
Quarter ended Sep 2026
Year ago EPS
-$0.95
Same quarter last year
Revenue
$353.2M
+192.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.42Dec '24Mar 2025: -$0.88Mar '25Jun 2025: -$0.95Jun '25Sep 2025: -$0.95Sep '25Dec 2025: -$0.99Dec '25Mar 2026: -$0.84Mar '26Jun 2026: -$0.78Jun '26Sep 2026: -$0.42Sep '26Latest -$0.42
Revenue by quarter
Dec 2024: $5.9MDec '24Mar 2025: $116.6MMar '25Jun 2025: $110.6MJun '25Sep 2025: $120.7MSep '25Dec 2025: $154.2MDec '25Mar 2026: $194.5MMar '26Jun 2026: $243.7MJun '26Sep 2026: $353.2MSep '26Latest $353.2M
How BBIO moved after its last 8 reports
Average move the session after a report ±4.0%
Oct 29, 2026After the close+6.0%
Aug 10, 2026After the close−1.1%
May 7, 2026After the close−0.1%
Feb 24, 2026After the close−2.6%
Jan 12, 2026After the close+3.0%
Oct 29, 2025After the close−4.9%
Aug 5, 2025After the close−8.9%
Apr 29, 2025After the close+5.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BBIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BBIO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BBIO

Technical Analysis

BBIO · as of the Nov 20 close · updated each morning
Turning up

The stock is 1% above its 20 day and 8% above its 50 day average. It is 4% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 55). The nearest support is the 100 day average at $75.49, and the nearest resistance the Pivot at $76.58.

Short trendBullish
Long trendNeutral
MomentumNeutral
StretchNormal
VolatilityNormal, 3.4%/day
Key levels
$93.4252 week high+22.9%
$77.69Pivot R1+2.2%
$76.81Swing high (Sep 9)+1.0%
$76.58Pivot+0.7%
$76.03Last close
$75.49100 day average−0.7%
$75.4220 day average−0.8%
$75.02Swing low (Aug 31)−1.3%
$74.91Pivot S1−1.5%
$72.76200 day average−4.3%
$70.3050 day average−7.5%
$62.5052 week low−17.8%
Indicators
RSI (14)54.90Middle of its rangeNeutral
MACD2.10Below its signal lineBearish
Stochastic57.0Middle of its rangeNeutral
ADX (14)36.9Trending up
Williams %R-62.8Oversold below −80, overbought above −20Neutral
CCI (20)31.3Oversold below −100, overbought above 100Neutral
Rate of change+2.3%Change over 10 sessionsBullish
ATR (14)$2.61Typical daily range, 3.4% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for BBIO

What happened before

See how BBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BBIOHow many large options trades hit BBIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

BBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲262 buying vs 223 selling
  • ▲Held by funds +17.9 pts
  • ▼Funds holding -8
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding484492−1.6%
In funds' top 1012120.0%
Held by funds125.0%107.1%+17.9 pts
New / increased65 / 19783 / 174+1.9%
Reduced / sold out149 / 74168 / 77−9.0%
Put/call ratio6.030.31+1861.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BBIO Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$90.8M32 sales · 7 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $8.3M2026-01 sold $6.0M2026-02 sold $11.4M2026-03 sold $10.3M2026-04 sold $6.1M2026-05 sold $8.8M2026-06 sold $14.5M2026-07 sold $14.8M2026-08 sold $3.7M2026-09 sold $691K2026-10 sold $146K2026-11 sold $4.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 19Neil KumarCEOSale plan54,980$77.86$4.3M
Oct 30Maricel ApuliChief Accounting OfficerSale plan2,000$72.85$146K
Sep 17Neil KumarCEOSale plan10,000$69.08$691K
Aug 19Neil KumarCEOSale plan44,980$82.86$3.7M
Jul 30Maricel ApuliChief Accounting OfficerSale plan2,000$80.06$160K
Jul 9Jennifer E. CookDirectorSale plan148,589$88.54$13.2M
Every insider buy and sale for BBIO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BBIO insider trades →

From SEC Form 4 filings by BBIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BBIO is in one of them and how their past BBIO trades turned out.

BBIO in the AI portfolios
Loading…

BBIO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BBIO in an article yet. Here's the latest on the wider market.

BBIO in the news

BBIO Congress Trades

All congress trades →
Trades, 12 months
8
Buys
7
88%
Sells
1
13%
People
1
Last filed Nov 10
Who traded BBIO · since 2025
Latest 5 filings of 10
$1K – $15KTraded Nov 2, 2026Filed Nov 10, 2026
$1K – $15KTraded Oct 27, 2026Filed Nov 10, 2026
Gilbert CisnerosSell (partial)
$1K – $15KTraded Sep 29, 2026Filed Oct 12, 2026
$1K – $15KTraded May 11, 2026Filed Jun 8, 2026
$1K – $15KTraded Apr 29, 2026Filed May 8, 2026
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KNov 2, 2026Nov 10, 20268 d
Gilbert CisnerosD · CABuy$1K – $15KOct 27, 2026Nov 10, 202614 d
Gilbert CisnerosD · CASell (partial)$1K – $15KSep 29, 2026Oct 12, 202613 d
Gilbert CisnerosD · CABuy$1K – $15KMay 11, 2026Jun 8, 202628 d
Gilbert CisnerosD · CABuy$1K – $15KApr 29, 2026May 8, 20269 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About BridgeBio Pharma

BridgeBio Pharma is a biopharmaceutical company based in Palo Alto, California, that develops medicines for people with genetic diseases. Its main commercial product is Attruby, a treatment for a heart condition caused by transthyretin amyloidosis, sold in the United States. The same medicine is sold under another name in Europe and Japan through partners. The company is also developing treatments for other rare conditions, such as achondroplasia and muscular dystrophy, for patients, physicians and healthcare providers.

Headquarters
Palo Alto, CA